On the heels of our recent Adicet Bio partnership, MaxCyte’s Senior Director of Innovation and Business Development Sean Menarguez shares the future of off-the-shelf T-cell therapies in this latest piece from BioProcess Insider. Learn more about: - How next-generation, non-viral T-cell platforms are shaping the landscape for scalable, allogeneic therapies - Why electroporation technology is enabling high-efficiency, non-viral cell engineering at clinical scale - What’s next for bridging innovative, non-viral research with real-world patient impact Read the full article here: https://bit.ly/4oGZbMc #CellTherapy #AllogeneicTCells #GeneEditing #FlowElectroporation #MaxCyte
